The insatiable and unmet demand for GLP-1 medications is unlikely to decrease anytime soon. Semaglutide - branded versions of which include Ozempic and Wegovy - was the top selling drug in the US, with net sales of $14 billion last year.

Recent research from Shi et al suggest that around 137 million adults in the US have conditions that make them medically eligible for treatment with it. That would include folk who meet the current criteria for needing it to assist with diabetes, weight management or cardiovascular disease.

A Venn diagram displays the overlap between adults eligible for semaglutide for diabetes, CVD, and weight management among the total eligible U.S. population of 136.8 million.

137 million people represents a little over a half of the estimate 250-million-ish adults in the US. Of that 137 million, around 15 million patients are currently estimated to be on a GLP-1.

There are signs in the research that GLP-1 drugs might help with a wide variety of other conditions. If they get approved for use beyond these three domains the number of course will only go up.